<div id="readability-page-1"><p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned an average rating of &#34;Buy&#34; from the nine ratings firms that are presently  covering the company, Marketbeat.com reports. One investment analyst  has rated the stock with a hold rating, seven have assigned  a buy rating and one  has issued  a strong buy rating on  the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $102.1429.</p><div><p><span></span><span>Get <strong>ANI Pharmaceuticals</strong> alerts:</span></p></div><p>Several equities analysts have weighed in on the company. Guggenheim raised their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, November 10th. HC Wainwright increased their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, September 17th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday. They set an &#34;overweight&#34; rating and a $100.00 price target on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st.</p><p><b>Check Out Our Latest Stock Report on ANIP</b></p><h2>Insider Buying and Selling at ANI Pharmaceuticals</h2><p>In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president owned 75,274 shares of the company's stock, valued at approximately $6,569,161.98. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of the firm's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director directly owned 25,157 shares of the company's stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,979 shares of company stock valued at $2,378,393 in the last ninety days. 11.10% of the stock is owned by corporate insiders. </p><h2>Institutional Trading of ANI Pharmaceuticals</h2><p>Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of  ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after purchasing an additional 2,220 shares during the last quarter.  National Bank of Canada FI bought a new position in  ANI Pharmaceuticals during the first quarter valued at $79,000.  Connor Clark &amp; Lunn Investment Management Ltd. increased its position in  ANI Pharmaceuticals by 202.7% in the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 46,750 shares of the specialty pharmaceutical company's stock worth $3,130,000 after buying an additional 31,308 shares during the last quarter.  Invesco Ltd. increased its position in  ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after buying an additional 2,022 shares during the last quarter.  Finally, Nuveen LLC bought a new stake in shares of  ANI Pharmaceuticals in the first quarter valued at $3,254,000. Institutional investors own  76.05% of the company's stock. </p><h2>ANI Pharmaceuticals Trading Up 0.1%</h2><p>NASDAQ:ANIP opened at $82.13 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The company has a market cap of $1.85 billion, a PE ratio of 50.39 and a beta of 0.48. The firm has a 50-day moving average of $87.79 and a 200-day moving average of $80.39. </p><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The business had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS.  As a group, equities research analysts expect that  ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year. </p><h2>ANI Pharmaceuticals Company Profile</h2> (Get Free Report)<p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p><h2>Read More</h2><ul><li>Five stocks we like better than ANI Pharmaceuticals</li><li>What is a penny stock? A comprehensive guide</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>Russell 2000 Index, How Investors Use it For Profitable Trading</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANIP

<p>ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus "Buy" rating from nine analysts, with a target price of $102.14. Insider trading saw VP Meredith Cook and Director Renee P. Tannenbaum sell shares, while institutional investors like Charles Schwab and Connor Clark & Lunn increased their stakes. The stock opened at $82.13, with a market cap of $1.85 billion and a PE ratio of 50.39. Recent earnings beat expectations with $2.04 EPS and $227.81 million revenue.</p>

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts